PL1623719T3 - Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej - Google Patents

Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej

Info

Publication number
PL1623719T3
PL1623719T3 PL04730882T PL04730882T PL1623719T3 PL 1623719 T3 PL1623719 T3 PL 1623719T3 PL 04730882 T PL04730882 T PL 04730882T PL 04730882 T PL04730882 T PL 04730882T PL 1623719 T3 PL1623719 T3 PL 1623719T3
Authority
PL
Poland
Prior art keywords
disease
alzheimer
treatment
amyloid angiopathy
cerebral amyloid
Prior art date
Application number
PL04730882T
Other languages
English (en)
Polish (pl)
Inventor
Barrio Manuel Sarasa
Original Assignee
Araclon Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araclon Biotech Sl filed Critical Araclon Biotech Sl
Publication of PL1623719T3 publication Critical patent/PL1623719T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PL04730882T 2003-05-08 2004-05-03 Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej PL1623719T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
EP04730882A EP1623719B1 (en) 2003-05-08 2004-05-03 Treatment of alzheimer's disease and cerebral amyloid angiopathy
PCT/ES2004/000194 WO2004098631A1 (es) 2003-05-08 2004-05-03 Método de tratamiento de la enfermedad de alzheimer

Publications (1)

Publication Number Publication Date
PL1623719T3 true PL1623719T3 (pl) 2010-11-30

Family

ID=32982086

Family Applications (3)

Application Number Title Priority Date Filing Date
PL04730882T PL1623719T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej
PL10012342T PL2356996T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera
PL08170222T PL2075007T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL10012342T PL2356996T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera
PL08170222T PL2075007T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera

Country Status (19)

Country Link
US (6) US20090162362A1 (enExample)
EP (5) EP2082747A3 (enExample)
JP (5) JP2006525288A (enExample)
CN (2) CN101264326A (enExample)
AT (1) ATE435024T1 (enExample)
AU (2) AU2004237373A1 (enExample)
BR (1) BRPI0410684A (enExample)
CA (1) CA2524571C (enExample)
CY (1) CY1109454T1 (enExample)
DE (1) DE602004021797D1 (enExample)
DK (3) DK2075007T3 (enExample)
ES (6) ES2246177B1 (enExample)
IL (8) IL171651A (enExample)
MX (1) MXPA05010914A (enExample)
PL (3) PL1623719T3 (enExample)
PT (3) PT2075007E (enExample)
RU (2) RU2385161C2 (enExample)
SI (1) SI1623719T1 (enExample)
WO (1) WO2004098631A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
CA2575663C (en) 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
MX358175B (es) 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
DK2238166T3 (da) * 2007-10-05 2014-01-27 Ac Immune Sa Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
AR079443A1 (es) 2009-12-11 2012-01-25 Araclon Biotech Sl Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
KR101790806B1 (ko) 2010-03-10 2017-11-20 프로비오드룩 아게 글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012009442A2 (en) * 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
AU2011282536B2 (en) * 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
ATE239797T1 (de) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
AU759945B2 (en) * 1998-08-20 2003-05-01 Regents Of The University Of California, The Methods for labeling beta-amyloid plaques and neurofibrillary tangles
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1975179A1 (en) * 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
AU2003250102B2 (en) * 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
CA2501945A1 (en) * 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Also Published As

Publication number Publication date
SI1623719T1 (sl) 2009-12-31
DK2356996T3 (da) 2013-07-22
IL207876A (en) 2013-03-24
PL2075007T3 (pl) 2013-09-30
EP2305286A2 (en) 2011-04-06
WO2004098631A1 (es) 2004-11-18
IL207878A (en) 2013-02-28
AU2004237373A1 (en) 2004-11-18
US20110262458A1 (en) 2011-10-27
PL2356996T3 (pl) 2013-09-30
IL207881A0 (en) 2011-07-31
IL207875A (en) 2013-02-28
PT2075007E (pt) 2013-08-23
MXPA05010914A (es) 2006-03-21
ATE435024T1 (de) 2009-07-15
EP2082747A2 (en) 2009-07-29
EP2356996B1 (en) 2013-06-26
IL207880A0 (en) 2011-07-31
ES2246105A1 (es) 2006-02-01
US20200140488A1 (en) 2020-05-07
EP2075007A2 (en) 2009-07-01
IL207881A (en) 2013-02-28
ES2423281T3 (es) 2013-09-19
BRPI0410684A (pt) 2006-06-20
EP2305286A3 (en) 2011-11-09
AU2011200170A1 (en) 2011-02-03
ES2246105B1 (es) 2007-03-01
AU2011200170C1 (en) 2012-03-22
EP2082747A3 (en) 2010-01-13
US20140044725A1 (en) 2014-02-13
IL207879A (en) 2013-02-28
US20170260234A1 (en) 2017-09-14
EP2356996B9 (en) 2013-08-28
CA2524571A1 (en) 2004-11-18
DK1623719T3 (da) 2009-11-09
IL207880A (en) 2013-02-28
IL207877A0 (en) 2011-07-31
EP2075007B1 (en) 2013-05-22
DK2075007T3 (da) 2013-07-29
DK2356996T5 (da) 2013-08-26
RU2009148539A (ru) 2011-06-27
ES2246177A1 (es) 2006-02-01
RU2005134351A (ru) 2006-04-27
JP2018119011A (ja) 2018-08-02
IL207879A0 (en) 2011-07-31
US20210214394A1 (en) 2021-07-15
CN101264326A (zh) 2008-09-17
CN1784240A (zh) 2006-06-07
AU2011200170B2 (en) 2011-09-01
JP2006525288A (ja) 2006-11-09
PT1623719E (pt) 2009-10-08
DE602004021797D1 (de) 2009-08-13
ES2246177B1 (es) 2007-03-01
CY1109454T1 (el) 2014-08-13
ES2246178A1 (es) 2006-02-01
IL207878A0 (en) 2011-07-31
ES2329369T3 (es) 2009-11-25
PT2356996E (pt) 2013-08-23
JP2016065100A (ja) 2016-04-28
JP2014129389A (ja) 2014-07-10
ES2423590T3 (es) 2013-09-23
ES2246178B1 (es) 2007-03-01
IL207876A0 (en) 2011-07-31
CA2524571C (en) 2017-01-10
EP2075007B9 (en) 2013-09-04
IL207877A (en) 2013-03-24
IL207875A0 (en) 2011-07-31
JP2012006967A (ja) 2012-01-12
EP2075007A3 (en) 2009-11-11
RU2385161C2 (ru) 2010-03-27
IL171651A (en) 2011-11-30
RU2526155C2 (ru) 2014-08-20
EP2356996A1 (en) 2011-08-17
US20090162362A1 (en) 2009-06-25
EP1623719A1 (en) 2006-02-08
EP1623719B1 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
PL1623719T3 (pl) Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej
EP1613347A4 (en) BETA AMYLOID PEPTIDE DETECTING HUMANIZED ANTIBODIES
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
WO2002074240A3 (en) Anti-amyloid antibody based diagnosis and treatment of a neurological disease or disorder
PL352717A1 (en) Prevention and treatment of amyloidogenic disease
DE60221665D1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
EP1578988A4 (en) TNF-ALPHA VARIANT-BASED PROTEIN FOR TREATMENT OF TNF-ALPHA ASSOCIATED DISORDERS
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DK2172208T3 (da) Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser
EP1543109A4 (en) SUBSTANCES FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES
TR200002626T2 (tr) Terkip
EP1749532A4 (en) MEDICINAL PRODUCTS FOR HEALING OR TREATING WOUNDS
WO2007021886A3 (en) Truncated memapsin 2 for use for treating alzheimer's disease
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE
WO2010024927A3 (en) Treatment of amyloidoses using myelin basic protein and fragments thereof
WO2005044301A3 (en) Use of specific histones for the treatment of parasitic diseases
EP1614428A4 (en) MEDICAMENT FOR PREVENTING OR TREATING ANGIOGENIC EYE DISEASES
WO2003087835A8 (en) Haptoglobin fragments diagnostic of alzheimers disease
HK1063639A (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2005067957A3 (en) Use of a dg147 protein product for preventing and treating metabolic disorders